55525
document
Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin . 1 . The potential interaction between racemic warfarin given as a 25 mg single oral dose and chronically administered ketorolac was studied in 12 young healthy male volunteers . 2 . Ketorolac produced no major change in the pharmacokinetics of ( R ) - or ( S ) -warfarin . 3 . Ketorolac did not alter the pharmacodynamic profile of racemic warfarin . 4 . Ketorolac increased template bleeding time by a factor of 1.35 as compared with placebo . 5 . The results suggest that the ketorolac-warfarin interaction is unlikely to be of major clinical significance ; however , combined use of ketorolac and warfarin in patients should be undertaken with due caution and appropriate monitoring .
55526
Intervention_Pharmacological
racemic warfarin
55527
Intervention_Pharmacological
racemic warfarin
55528
Intervention_Pharmacological
25 mg single oral dose and chronically administered ketorolac
55529
Intervention_Pharmacological
Ketorolac
55530
Intervention_Pharmacological
Ketorolac
55531
Intervention_Pharmacological
Ketorolac
55532
Intervention_Pharmacological
ketorolac
55533
Intervention_Pharmacological
warfarin
55534
Outcome_Physical
pharmacokinetics and pharmacodynamics of racemic warfarin
55535
Outcome_Physical
no major change in the pharmacokinetics of ( R ) - or ( S ) -warfarin
55536
Outcome_Physical
did not alter the pharmacodynamic profile of racemic warfarin
55537
Outcome_Physical
increased template bleeding time
55538
Participant_Sample-size
12
55539
Participant_Age
young
55540
Participant_Condition
healthy
55541
Participant_Sex
male